DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Maxalt-Mlt (Rizatriptan Benzoate) - Summary

 
 



MAXALT-MLT SUMMARY

MAXALT Tablets and MAXALT-MLT Orally Disintegrating Tablets contain rizatriptan benzoate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist.

MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults.

MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population.


See all Maxalt-Mlt indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Maxalt-Mlt (Rizatriptan)

Cosmetic Eye Procedure May Ease Migraines, Small Study Says
Source: MedicineNet Headache Specialty [2014.08.25]
Title: Cosmetic Eye Procedure May Ease Migraines, Small Study Says
Category: Health News
Created: 8/22/2014 12:36:00 PM
Last Editorial Review: 8/25/2014 12:00:00 AM

Cosmetic eyelid surgery technique effective for migraine relief
Source: Cosmetic Medicine / Plastic Surgery News From Medical News Today [2014.08.04]
Dr. Oren Tessler, Assistant Professor of Clinical Surgery at LSU Health Sciences Center New Orleans School of Medicine, is part of a team of plastic and reconstructive surgeons who report a high...

Symptom relief following non-endoscopic migraine surgery
Source: Cosmetic Medicine / Plastic Surgery News From Medical News Today [2014.07.31]
A revised version of a surgical procedure to treat severe chronic migraine headaches led to significant symptom relief more than 90 percent of the time in patients treated at Massachusetts General...

Older people with migraines 'more likely to have silent brain injury'
Source: Headache / Migraine News From Medical News Today [2014.05.16]
Migraine sufferers who are older have double the chances of experiencing 'silent strokes,' compared with individuals who do not have migraines, say researchers.

New drugs offer hope for migraine prevention
Source: Headache / Migraine News From Medical News Today [2014.04.25]
Two new studies may offer hope for people with migraine. The two studies will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

more news >>

Published Studies Related to Maxalt-Mlt (Rizatriptan)

Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. [2011.05]
OBJECTIVE: The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. BACKGROUND: Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100 mg non-responders will respond to other triptans... CONCLUSION: Rizatriptan 10-mg ODT was superior to placebo at providing two-hour pain relief and two-hour pain freedom in the treatment of acute migraine in those who do not respond to sumatriptan 100 mg. Rizatriptan was generally well tolerated in this population.

A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. [2011.04]
The objective of this study was to assess patient satisfaction with acute treatment of migraine with frovatriptan or rizatriptan by preference questionnaire. 148 subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack per month in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or rizatriptan 10 mg treating 1-3 attacks...

Rizatriptan reduces vestibular-induced motion sickness in migraineurs. [2011.02]
A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation. In this double-blind, randomized, placebo-controlled study we measured motion sickness in response to a complex vestibular stimulus following pretreatment with either rizatriptan or a placebo...

Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. [2011]
The objectives of this study are to assess the efficacy and safety of frovatriptan, and rizatriptan in the subgroup of women with menstrually related migraine of a multicenter, randomized, double blind, cross-over study. Each patient received frovatriptan 2.5 mg or rizatriptan 10 mg in a randomized sequence: after treating 3 episodes of migraine in not more than 3 months with the first treatment, the patient had to switch to the other treatment...

A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. [2009.08.06]
CONCLUSIONS: These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness potentiation by cranial pain.

more studies >>

Clinical Trials Related to Maxalt-Mlt (Rizatriptan)

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops [Recruiting]

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents [Recruiting]

Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-Autonomic Symptoms. [Not yet recruiting]
Triptans are first choice drugs in the acute treatment of migraine and cluster headache. However, while in cluster headache the response rate to subcutaneous sumatriptan is 96%, around 30% of patients fail to respond to a particular triptan4. Nonresponse is likely to be due to a variety of factors, including low and inconsistent absorption, inadequate dosing, and variability in individual response5. Timing of administration is also a crucial issue. In fact, an early treatment of the attack, when the pain is still mild, may increase the responders rate by circumventing the development of cutaneous allodynia (expression of central sensitization of pain pathway) during the course of the attack6,7.

Several studies have been performed in an attempt to genetically, psychologically and clinically characterize the triptan responders but failed to provide conclusive results8-10.

Nevertheless, we suggested that the presence of UAs during the migraine attack might predict a good response to triptans1,11. UAs are common in migraine patients. They have been reported in almost one out of two migraineurs (45. 8%) attending a tertiary headache centre and in more than one out of four (26. 9%) in a population-based study1,3. In an open study with sumatriptan 50 mg performed on 72 migraine patients with UAs, we described pain relief in 65. 3% of the patients at 1 h and in 81. 9% at 2 h, while pain-free in 30. 6% at 1 h and in 61. 1% at 2 h11. We hypothesized a large-scale recruitment of peripheral neurovascular 5-HT1B/1D receptors consequent to the activation of the trigeminal-autonomic reflex in such patients. Our hypothesis has received further confirmation by the demonstration of higher levels of calcitonin gene-related peptide, neurokinin A and vasoactive intestinal peptide (the hallmark of the activation of the trigeminal autonomic reflex) in external jugular blood in rizatriptan responders than in non-responders 12.

The investigators therefore postulate that migraineurs with UAs may respond better to rizatriptan than "general" migraine population.

Objectives:

To evaluate the efficacy of rizatriptan 10 mg lyophilized wafer (MLT) compared to placebo in the treatment of acute migraine in patients with unilateral autonomic symptoms (UAs: unilateral lacrimation, eye redness, eyelid oedema, nasal congestion or rhinorrhoea, miosis or ptosis, forehead or facial sweating) during the attack

Rizatriptan 10 MG RPD in the Treatment of Acute Migraine [Recruiting]
This is a multicentre, open label, prospective, randomized, two-attack study with active comparator in patients reporting inadequate response to analgesics and/or triptans to examine the efficacy of Rizatriptan 10 mg RPD in this group of patients.

Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response? [Recruiting]
Researchers want to learn about work productivity after treatment of a migraine headache with your usual migraine medication as compared to your work productivity after treatment with Treximet.

During this research subjects will take Treximet to treat 3 workday migraine attacks. For a second part of the research subjects will take their usual prescribed medication for 3 workday migraine attacks. The subjects will complete questionnaires after treating each migraine.

more trials >>

Reports of Suspected Maxalt-Mlt (Rizatriptan) Side Effects

Drug Ineffective (3)Intestinal Ischaemia (2)Vomiting (2)Epilepsy (2)Abdominal Pain (1)Cardiac Tamponade (1)Contusion (1)Sudden Death (1)Abortion Spontaneous (1)Drug Label Confusion (1)more >>


Page last updated: 2014-08-25

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014